Cidara Therapeutics, Inc. (CDTX) - Comprehensive Stock Analysis & Investment Research
Deep dive into Cidara Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Cidara Therapeutics, Inc. Investment Summary
When evaluating whether Cidara Therapeutics, Inc. (CDTX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Cidara Therapeutics, Inc. (CDTX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 81 people. With a market capitalization of $6 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.
Financial Performance Analysis
Our comprehensive financial analysis covers Cidara Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Cidara Therapeutics, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Cidara Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Cidara Therapeutics, Inc. (Stock Symbol: CDTX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Cidara Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cidara Therapeutics, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Cidara Therapeutics, Inc....
Revenue & Growth Analysis
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Cidara Therapeutics, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Cidara Therapeutics, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Cidara Therapeutics, Inc....
Strategic Market Position
Cidara Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.
Industry Competitive Landscape
Cidara Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-47 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 73.3% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.
Operating margin of -605.8% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 0.99x indicates solid asset utilization efficiency appropriate for many manufacturing or mixed business models. This level suggests the company generates meaningful revenue from its asset base while maintaining necessary capital investments for operations.
Financial Strength & Leverage
Current ratio of 1.62 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.